drugs week 8

HideShow resource information
  • Created by: hadar
  • Created on: 04-05-16 10:16
Bleomycin- mechanism of action
bleomycin chelates metal ions (primarily iron) producing a pseudoenzyme that reacts with oxygen to produce superoxide and hydroxide free radicals that cleave DNA.
1 of 18
Dacarbazine- mechanism of action
inhibition of protein, RNA and DNA synthesis- inhibit transmethylation of methyl groups of methionine into t-RNA- production of hydrogen peroxide
2 of 18
ABVD regimen
Doxirubicin/ bleomycin/ vinblastin/ dacarbazine (1 cycle/ 4 weeks/ 2 doses) HODGKIN LYMPHOMA
3 of 18
Cyclophosphamide- mechanism of action
alkylating agent- 1) attachment of alkyl groups to DNA bases 2) DNA damage via the formation of cross-links 3) the induction of mispairing of the nucleotides leading to mutations.
4 of 18
vincristine- mechanism of action
to inhibition of mitosis at metaphase through its interaction with tubulin. (like vinblastine)
5 of 18
Etoposide- mechanism of action
inhibits DNA topoisomerase II, thereby inhibiting DNA re-ligation. cell cycle dependent and phase specific, affecting mainly the S and G2 phases of cell division.
6 of 18
Prednisone- mechanism of action
glucocorticoid receptor agonist/ phospholipase A2 inhibitory proteins, which control the biosynthesis mediators of inflammation- B cell differentiation depends on pro inflammatory cytokines inhibit the pathway which they proliferate and differentiate
7 of 18
STANFORD V regimen
doxirubicin/ vinblastine/ cyclophosphamide/ vincristine/ bleomycin/ etoposide/ prednisone HODGKIN LYMPHOMA
8 of 18
BEACOPP regimen
bleomycin/ etoposide/ doxirubicin/ cyclophosphamide/ vincristine/ procarbazine/ prednisone HODGKINS LYMPHOMA
9 of 18
MOPP regimen
cyclophosphamide/ vincristine/ procarbazine/ prednisone HODGKINS LYMPHOMA
10 of 18
EPOCH regimen
etoposide/ prednisolone/ vincristine/ cyclophosphamide/ doxirubicine (rituximab) NON HODGKIN LYMPHOMA
11 of 18
prednisolone- mechanism of action
glucocorticoid receptor agonist
12 of 18
Cytarabine- mechanism of action
it combines cytosine with arabinose sugar cytosine arabinose structurally similar to cytosindeoxyribose instead of the right base introducing a wrong sugar changing DNA synthesis dynamics -destabilizes DNA- inhibiting DNA synthesis- cell death
13 of 18
Anthracyclines - mechanism of action
4 mechanisms 1. topoisomerase II inhibition 2. crosslinkning 3. histone eviction 4. oxygen free radicle generation
14 of 18
Rituximab - mechanism of action
binds to the CD20 antigen on B lymphocytes, while the Fc domain recruits antibodies and complements to mediate cell lysis. And recruits NK cells → antibody dependant cellular cytotoxicity. Induction of ADCC and complement
15 of 18
Thalidomide- mechanism of action
1-antiangiogenic 2- oxygen free radicles 3- modulates different types of cytokines → needed for terminal differentiation of plasma cells
16 of 18
Dexamethasone - mechanism of action
glucocorticoid agonist (Suppresses proinflammatory and promotes anti-inflammatory cytokines) upregualting phospholipase A2 inhibitory proteins
17 of 18
Imatinib- mechanism of action
inhibitor of a number of tyrosine kinase enzymes- blocks BCR-Abl enzyme, and stops it from adding phosphate groups- inhibit cell signalling cascade- cells stop growing, and even die by a process of cell death (apoptosis)
18 of 18

Other cards in this set

Card 2

Front

inhibition of protein, RNA and DNA synthesis- inhibit transmethylation of methyl groups of methionine into t-RNA- production of hydrogen peroxide

Back

Dacarbazine- mechanism of action

Card 3

Front

Doxirubicin/ bleomycin/ vinblastin/ dacarbazine (1 cycle/ 4 weeks/ 2 doses) HODGKIN LYMPHOMA

Back

Preview of the back of card 3

Card 4

Front

alkylating agent- 1) attachment of alkyl groups to DNA bases 2) DNA damage via the formation of cross-links 3) the induction of mispairing of the nucleotides leading to mutations.

Back

Preview of the back of card 4

Card 5

Front

to inhibition of mitosis at metaphase through its interaction with tubulin. (like vinblastine)

Back

Preview of the back of card 5
View more cards

Comments

No comments have yet been made

Similar Accounting resources:

See all Accounting resources »See all pharma resources »